Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Notes Payables (2016 - 2018)

Historic Notes Payables for Marker Therapeutics (MRKR) over the last 4 years, with Q3 2018 value amounting to $5000.0.

  • Marker Therapeutics' Notes Payables changed 0.0% to $5000.0 in Q3 2018 from the same period last year, while for Sep 2018 it was $5000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $5000.0 for FY2017, which is 0.0% changed from last year.
  • As of Q3 2018, Marker Therapeutics' Notes Payables stood at $5000.0, which was down 0.0% from $5000.0 recorded in Q2 2018.
  • Marker Therapeutics' 5-year Notes Payables high stood at $52942.0 for Q1 2015, and its period low was $5000.0 during Q3 2016.
  • Its 4-year average for Notes Payables is $18655.1, with a median of $5000.0 in 2016.
  • In the last 5 years, Marker Therapeutics' Notes Payables crashed by 9055.57% in 2016 and then changed by 0.0% in 2017.
  • Marker Therapeutics' Notes Payables (Quarter) stood at $30000.0 in 2015, then plummeted by 83.33% to $5000.0 in 2016, then changed by 0.0% to $5000.0 in 2017, then changed by 0.0% to $5000.0 in 2018.
  • Its Notes Payables was $5000.0 in Q3 2018, compared to $5000.0 in Q2 2018 and $5000.0 in Q1 2018.